# Memantine in the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1108 - Language: en - Last updated: not specified - Page title: Memantine in the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis | WCP 2026 Summary > Evidence for the benefit of memantine as an adjunctive treatment for obsessive-compulsive disorder is mixed, with the strongest signal observed in treatment-re… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1108) Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun. EV1108 E-PosterPsikofarmakolojiSistematik derleme # Memantine in the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis MEMANTINE FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER: A SYSTEMATIC REVIEW AND NARRATIVE SYNTHESIS Sunan: Joshua W. Bryan Ülke: United Kingdom Kurum: Cardiff University School of Medicine Evidence for the benefit of memantine as an adjunctive treatment for obsessive-compulsive disorder is mixed, with the strongest signal observed in treatment-resistant cases, although this finding has not been replicated. The aim is to critically evaluate the efficacy, dosing strategies, treatment duration, tolerability, and adverse effects of memantine as an adjunctive treatment for obsessive-compulsive disorder (OCD), as well as the methodological limitations of the existing literature. A structured MEDLINE search was conducted using the terms memantine, obsessive compulsive disorder, and glutamat*, supplemented by forward and backward citation searching; studies of memantine at any dose and for any duration were eligible, while animal studies, case reports, non-English publications, and studies that did not primarily investigate memantine were excluded. The primary outcome was change in OCD symptom severity, assessed mainly using the Y-BOCS, and secondary outcomes were cognitive function and tolerability; owing to substantial heterogeneity in populations, designs, dosing, and outcome measures, a narrative synthesis was conducted rather than a meta-analysis. The initial search in March 2024 identified 42 records, and a second search in August 2025 identified 5 records; 10 studies were included in the review. Evidence of efficacy is mixed: four studies reported improvements in obsessive-compulsive symptoms, but methodological weaknesses such as small samples, participant attrition, and inadequate intention-to-treat analyses reduced confidence in these positive findings. The strongest signal was observed in treatment-resistant OCD; in the only study that rigorously recruited a treatment-resistant population, adjunctive memantine produced significantly lower Y-BOCS scores than placebo (p < 0.001), with 73.3% of patients achieving a treatment response, but this finding has not been replicated. The most frequently reported adverse effects were nausea, dizziness, headache, and somnolence; higher doses, particularly 20 mg/day, were associated with more frequent adverse effects, while lower doses were better tolerated but showed less consistent efficacy, and the optimal dose could not be established. In the most recent randomized controlled trial included in the review, both groups improved, but adjunctive memantine showed no significant advantage over escitalopram alone in terms of Y-BOCS scores, with benefit observed only in the time-management domain of executive functioning; studies with larger samples, standardized dosing, a clear definition of treatment resistance, and long-term follow-up are needed. [Orijinal postere git](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/394) Bu çalışmaya nasıl atıf yapılır? APA 7: Bryan, J. W., et al. (2026, September 23-26). Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/394 Vancouver: Bryan JW, et al. Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/394 Yazar adları ve başlık biçimi kongre sisteminden otomatik oluşturulmuştur; kullanmadan önce orijinal posterle karşılaştırın. ## Aynı konudan - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [Tüm WCP 2026 özetleri](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1108 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim